Want to join the conversation?
$VRX said it agreed to divest all North American commercialization rights to Ruconest (recombinant human C1 esterase inhibitor) to Pharming Group. Pharming will pay $VRX aggregate consideration of up to $125MM, including upfront fee of $60MM payable upon closing and certain sales-based milestone payments of up to $65MM.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)